Intuitive Surgical, Inc.

The transcript does not explicitly mention current or expected orderbook or pending orders. However, relevant information includes: - Demand for da Vinci 5 systems is increasing, with broad launches planned as supply chains scale and clearances expand geographically. - Trade-ins for da Vinci 5 systems are expected to pick up progressively starting mid-year, tied to broader launch timing. - The company is managing capital placements, including strong activity in the US and challenges in regions like China, UK, Germany, and Japan due to competitive and governmental factors. - Procedure growth is anticipated between 13% to 16% in 2025, indicating ongoing demand for systems and accessories. - Competitive dynamics, especially from new entrants and domestic competitors in China, may impact selling cycles and potentially lengthen sales timing. No specific figures or detailed order backlog quantities are provided in the available text.

- The transcript does not mention any current or planned fundraising through debt or equity. - Capital expenditure for 2025 is expected between $650 million and $800 million, primarily for facility construction, but funding sources are not specified. - Cash and investments increased to $8.8 billion at the end of Q4 2024, suggesting strong liquidity without immediate need for fundraising. - No references to issuing new debt or equity to finance operations or growth initiatives. - No discussion of upcoming equity offerings or debt issuances in the Q&A or prepared remarks. - The company noted cautious observation of potential tariff impacts but did not indicate raising capital in response. - Acquisition of da Vinci business in Southern Europe was announced with a structured payment, but funding details were not disclosed.

- Capital expenditure guidance for 2025 is projected between $650 million and $800 million, primarily for planned facility construction activities. - Investments in innovation to drive growth objectives will contribute to operating expenses growth of 10%-15% in 2025. - Increased depreciation from new facilities and new products, including da Vinci 5, Ion, and SP platforms, will impact gross profit margin. - Management is pursuing geographic expansion with strategic acquisitions, including the recent purchase of da Vinci business in Italy, Spain, Portugal, and related territories from ab medica for EUR290 million plus earn-outs. - Significant investment in R&D continues, exceeding $1 billion annually, targeting new platforms, additional indications, imaging capabilities, and force feedback instruments (broad supply expected by late 2025). - Efforts include supporting latecomers to robotics with tailored solutions and scaling up supply chains for broad da Vinci 5 launch globally.

- Total da Vinci procedure growth projected at 13%-16% in 2025, following 17% growth in 2024. - Volume growth supported by expansion of da Vinci 5 system placements and increased utilization of SP and Ion platforms. - Continued procedure growth expected in the US, with international growth dependent on improving capital environments, especially in China and Europe. - Increasing competition, particularly in China, may lengthen sales cycles and impact pace of growth. - Instruments and accessories revenue growth linked to product mix changes and procedural volume, with potential uplift from force feedback instruments anticipated broadly by late 2025. - Operating expenses expected to rise 10-15% in 2025 to support innovation and commercial expansion. - Capital expenditures between $650 million and $800 million to facilitate growth infrastructure. - Margin pressure expected in 2025 due to higher depreciation from new products and mix of lower-margin platforms but midterm gross margin recovery targeted above 70%. - Strategic international acquisitions aimed at augmenting long-term revenue growth.

- 2025 pro forma operating expenses expected to grow 10%-15%, reflecting increased depreciation from new facilities, innovation investments, and higher legal expenses. - Pro forma gross profit margin for 2025 guided between 67%-68%, lower than 2024's 69.1% due largely to increased depreciation, product mix shifts toward lower-margin Da Vinci 5, Ion, and SP platforms, and currency impact. - Midterm expectation to return gross margin above 70% after leveraging depreciation and ongoing margin improvements in Ion and SP products. - Pro forma income tax rate projected at 22%-23% for 2025, slightly higher than 2024's 21.4%. - Continued revenue growth driven by 13%-16% procedure increase projected for 2025. - Operating income growth expected but tempered by margin pressures and higher operating expenses. - Net income and EPS growth anticipated over time with expansion in integrated instruments/accessories and market penetration of new platforms.